Dr. David Goodman, CEO of Pharmascience, talks about the strategy for the international expansion of the company, key for which are long-lasting partnerships. He also analyzes the re-organization of the company amongst the two main axes of generics and branded products and highlights its dedication to R&D, especially in the generic oral and injectable fields as well as in innovative gastroenterology, and hospital-based formulation improvements primarily for the unmet pediatrics population.
David, when we last spoke in 2013, you wanted to expand your international business and be recognized as one of Canada’s strongest diversified pharmaceutical companies. What have been some of the major milestones of the evolution of Pharmascience over the last four years?
"Pharmascience already offers a great platform to distribute and market biosimilars in the markets and therapeutic areas we are strong in."
